Commentary: Takeda/Alnylam Best Alliance Deal Of 2008?
This article was originally published in PharmAsia News
Takeda Pharmaceuticals' May collaboration with U.S.-based Alnylam and its RNAi work was one of the best deals in that class of drugs in 2008. The move even topped Takeda's alliance with Amgen and acquisition of Millennium, both of the United States, earlier in the year. The Anylam alliance also could help the American company gain access to candidate drugs under development by other drug makers and even obtain a partner for its RNAi work elsewhere in Asia. All of that is in addition to the alliance's arrangement for Alnylam to share in marketing rights for up to four Takeda programs of Alnylam's choosing. It also allows Alnylam to finish the year with $500 million during a global financial crisis. (Click here for more
You may also be interested in...
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.
US FDA investigators' increased focus on aseptic operations is resulting in more Form 483 observations of microbiological contamination issues over the past few years.